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ABSTRACT
Role of the Opioid System in the Behavioral Deficit Observed after Uncontrollable
Shock.  (May 2005)
Stephanie Nicole Washburn, B.A., Texas A&M University
Chair of Advisory Committee: Dr. James W. Grau
Spinal cord neurons can support a simple form of instrumental learning that can
be used to assess behavioral potential (plasticity) within this system.  In this paradigm,
subjects completely transected at the second thoracic vertebra learn to minimize shock
exposure by maintaining a hindlimb in a flexed position.  Preexposure to uncontrollable
shock (shock independent of leg position) disrupts this learning.
Activation of opioid receptors seems to contribute to the expression of the
behavioral deficit observed after uncontrollable shock.  Intrathecal application of
naltrexone, a nonselective opioid receptor antagonist, blocked the expression, but not the
induction, of the deficit.  Treatment with nor-BNI, a kappa receptor antagonist, prior to
testing had a similar effect, whereas mu (CTOP) and delta (naltrindole) receptor
antagonists did not block the deficit.  These findings suggest that prior exposure to
uncontrollable shock induces a kappa opioid mediated event that inhibits learning.  The
current study examined the role of the kappa receptor in the behavioral deficit. Only
GR89696, a selective kappa-2 receptor agonist, inhibited learning.  This impairment was
dose-dependent and, at the highest dose (30 nmol), inhibited learning for 96 hours.
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However, GR89696 and uncontrollable shock did not interact in an additive fashion.
Instead, an intermediate dose attenuated the induction of the deficit.  These findings
suggest that activation of kappa receptors, specifically the kappa-2 subtype, inhibit
instrumental learning and block the induction of the learning deficit.  Both effects may
be linked to the inhibition of NMDA-mediated plasticity.
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1INTRODUCTION
Researchers have challenged the claim that the spinal cord is immutable by
demonstrating that it can support simple forms of learning, including habituation,
sensitization, and even Pavlovian and instrumental conditioning (Beggs, Steinmetz,
Romano, & Patterson, 1983; Beggs, Steinmetz, & Patterson, 1985; Buerger & Fennessy,
1970; Chopin & Buerger, 1976; Fitzgerald & Thompson, 1967; Grau, Barstow, &
Joynes, 1998; Patterson, Cegavske, & Thompson, 1973; Thompson & Spencer, 1966).
Our laboratory uses an instrumental learning paradigm to assess spinal cord plasticity
and to study the underlying neurobiological mechanisms of learning (Grau et al., 1998).
In this paradigm, subjects undergo complete transection of the spinal cord and are placed
into a tube that allows the hind limbs to hang freely.  Whenever one hind limb falls
below a set criterion, a shock is delivered to the tibialis anterior muscle, causing a
reflexive upward flexion of the limb, which terminates the shock (controllable shock).
Over the 30-minute training period, rats gradually learn to maintain the hind limb in a
flexed position, effectively minimizing shock exposure.  Animals exposed to
uncontrollable shock (shock independent of leg position) fail to learn the relationship
between limb position and shock onset when later tested with controllable shock.  This
behavioral deficit lasts up to 24 hours (Crown, Joynes, Ferguson, & Grau, 2002).
Previous studies have shown that both instrumental learning and the development
of the behavioral deficit require NMDA-dependent processes (Ferguson, Crown, Patton,
& Grau, 2002; Ferguson, Hook, & Grau, 2004; Joynes, Janjua, & Grau, 2004).  NMDA
receptor antagonists block both the acquisition and maintenance of the instrumental
____________
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2response when given prior to and during testing, respectively.  This finding is not
surprising in light of the fact that most forms of long-term potentiation (LTP), a
phenomenon regarded as the biological substrate of learning and memory (Bliss &
Lomo, 1973; Lynch & Baudry, 1984; Madison, Malenka, & Nicoll, 1991), require
NMDA receptor function (Morris, Anderson, Lynch, & Baudry, 1986).  Central
sensitization, which is thought to underlie the development of hyperalgesia (enhanced
pain) and allodynia (a previously nonpainful stimulus becomes painful), depends on
many of the same molecular events as LTP, including NMDA receptor activation
(Coderre, 1993; Dickenson, 1990, 1996; Dray, Urban, & Dickenson, 1994; Ji, Kohno,
Moore, & Woolf, 2003; Wall & Woolf, 1984; Willis, Sluka, Rees, & Westlund, 1996;
Woolf, 1983, 1984). A number of studies have shown that NMDA receptor antagonists
are antihyperalgesic (Ren, Hylden, Williams, Ruda, & Dubner, 1992a; Ren, Williams,
Hylden, Ruda, & Dubner, 1992b; Ren & Dubner, 1993).  These same antagonists can
prevent the development of the behavioral deficit if given prior to uncontrollable shock,
suggesting that it also is dependent upon NMDA receptor activation (Ferguson et al.,
2002, 2004).  Interestingly, inflammatory agents routinely used in experimental models
of central sensitization (e.g., carrageenan and formalin) mimic the effects of
uncontrollable shock (Ferguson, Crown, Washburn, Miranda, & Grau, 2001; Huie,
Ferguson, & Grau, 2004).   Furthermore, a tactile allodynia accompanies the
development of the deficit after uncontrollable shock (Ferguson, Crown, Dhruv,
Washburn, & Grau, 2000), suggesting that the deficit may be linked to central
sensitization.  Based on these findings, we have argued that instrumental learning
3requires a selective, NMDA-dependent modification in a particular response pathway
(Ferguson et al., 2002, 2004; Grau et al., 1998; Joynes et al., 2004) and that
uncontrollable shock disrupts this learning by inducing a form of overexcitation that
diffusely saturates NMDA-mediated plasticity (Moser, Krobert, Moser, & Morris, 1998;
Moser & Moser, 1999).
Opioid receptors, specifically the kappa subtype, seem to play a role in the
expression of the behavioral deficit induced by uncontrollable shock.  For example,
intrathecal administration of naltrexone blocked the expression, but not the induction, of
the behavioral deficit (Joynes & Grau, 2004).  Subsequent studies revealed that the
kappa antagonist nor-BNI had a similar effect. Mu (CTOP) and delta (naltrindole)
receptor antagonists did not prevent the behavioral deficit, indicating that only kappa
receptors are involved.  Collectively, these results suggest that uncontrollable shock
initiates a kappa receptor-mediated event that inhibits learning.  Interestingly, dynorphin,
an endogenous opioid peptide highly selective for the kappa receptor subtype, has been
implicated in the pathophysiology of a variety of conditions, including Alzheimer’s
disease, traumatic brain injury, and spinal cord trauma (Caudle & Isaac, 1988; Faden,
1996). Studies have shown that opioid antagonists protect against the neuropathology
observed in several experimental injury models (for a review see Faden, 1993).  Using
naloxone, Faden and colleagues (1981a, 1981b) showed a significant reduction in
posttraumatic ischemia and improved behavioral recovery after cervical spinal cord
injury in the cat.  Additional studies identified the kappa receptor as the primary
mediator of the pathophysiological actions of dynorphin (Faden, Takemori, &
4Portoghese, 1987). High doses of intrathecal dynorphin results in maladaptive changes in
the spinal cord, including hind limb paralysis, an irreversible loss of the tail-flick reflex,
and release of excitatory amino acids (Bakshi, Newman, & Faden, 1990c; Caudle &
Isaac, 1987; Faden & Jacobs, 1983).  These effects can be blocked or reversed using
NMDA antagonists, suggesting that the neurotoxic actions of dynorphin result from
potentiation of NMDA receptor activity (Bakshi & Faden, 1990a, 1990b; Bakshi, Ni, &
Faden, 1992; Caudle & Isaac, 1988).  Modulation of excitatory amino acids may
underlie this potentiation and the resulting neurotoxic consequences (Caudle & Isaac,
1988; Skilling, Sun, Kurtz, & Larson, 1992).  Presumably, uncontrollable shock would
cause the release of dynorphin.  Based on our theory that the behavioral deficit results
from a form of NMDA-mediated overexcitation within the spinal cord, this release may
mediate the consequences of uncontrollable shock.
Although the activation of kappa receptors is thought to underlie the pathology
observed after injury, a number of other studies have shown that some kappa agonists
are protective in these same injury models (Birch et al., 1991; Hall, Wolf, Althaus, &
Von Voigtlander, 1987).  Treatment with selective kappa-2 agonists, both before and
after cerebral ischemia, reduced neuronal cell loss in the CA1 region of the hippocampus.
Others have shown that GR89696, a kappa-2 agonist, prevents and reverses hyperalgesia
and allodynia in animal models of inflammation, neuritis, and neuropathy (Eliav,
Herzberg, & Caudle, 1999; Ho, Mannes, Dubner, & Caudle, 1997). These
neuroprotective effects can be reversed with opioid receptor antagonists, indicating that
opioid receptors mediate these effects (Birch et al., 1991; Eliav et al., 1999).
5Electrophysiological studies have shown that kappa-2 receptor activation inhibits current
flow through the NMDA receptor (Caudle, Chavkin, & Dubner, 1994), and kappa
agonists have been shown to presynaptically inhibit glutamate release (Werz &
McDonald, 1983).  This inhibition of synaptic current and transmitter release has been
demonstrated in both the brain (Caudle et al., 1994; Wagner, Caudle, & Chavkin, 1992;
Wagner, Terman, & Chavkin, 1993) and spinal cord (Randic, Cheng, & Kojic, 1995;
Werz & McDonald, 1985). These NMDA inhibitory actions are thought to underlie the
neuroprotection provided by kappa agonists (Ho et al., 1997; Birch et al., 1991).  If this
is true, then GR89696 may prevent the induction of the deficit if given prior to
uncontrollable shock.  However, it may also prevent learning if given immediately
before testing due to its inhibition of NMDA receptor function.
The two divergent models of the effects of kappa agonists on NMDA receptor
function (potentiation vs. inhibition) lead to very different predictions in the
investigation of their role in the behavioral deficit.  Table 1 depicts these differential
predictions.  If kappa agonists induce NMDA-mediated overexcitation of spinal cord
neurons, as suggested in model A, then they should substitute for uncontrollable shock,
which is also thought to induce a form of overexcitation (Joynes et al., 2004).
Acquisition of the instrumental response is disrupted when this overexcitation reaches a
level that saturates NMDA-mediated plasticity.  High doses of kappa agonists that excite
spinal cord neurons beyond this level should impair instrumental learning and may even
cause cell loss that permanently abolishes the capacity for learning (Caudle & Isaac,
1987).  Low doses that cause excitation not exceeding this threshold may actually
6facilitate instrumental learning and should have no long-term impact.  However,
according to model A, if combined with uncontrollable shock, these same doses should
exacerbate the behavioral deficit.  Overall, the predictions made by model A suggest that
kappa agonists, at least at high concentrations, are detrimental to spinal cord function.
Model B, which suggests that kappa agonists inhibit this receptor system, also
predicts that these agonists will impair instrumental learning if given immediately before
testing.  This prediction is based on the finding that NMDA receptor antagonists disrupt
instrumental learning when active in the spinal cord (Joynes et al., 2004).  However, in
contrast to model A, model B suggests that this impairment will occur independent of
dose.  Any dose that sufficiently inhibits NMDA receptor activation should induce a
behavioral deficit when active in the system.  Unlike model A, model B predicts that
neither high nor low doses of a kappa agonist will have a long-term impact and that once
Impact on Instrumental
Learning
Long-Term
Effect
Interaction
with Shock
Biochemical Model A:
NMDA Facilitation
Facilitation at low doses
Disruption at high doses
At high
Doses
Additive
Biochemical Model B:
NMDA Inhibition
Disruption at high and
low doses
Not
Anticipated
Protective
Table 1.  Table illustrating the predictions made by the theory of NMDA receptor facilitation (model A)
versus those made by the theory of NMDA receptor inhibition (model B).  Both models predict that
kappa agonists will impair instrumental learning.  However, model A predicts that this impairment will be
dose-dependent, whereas model B predicts impairment at all effective dosages.  Long-term effects are
predicted by model A, but not by model B.  The potentiation of NMDA receptors by kappa agonists
suggests that these agents will exacerbate the consequences of uncontrollable shock.  Model B makes the
opposite prediction: that kappa agonists will protect against uncontrollable shock.
7the drug has cleared the system, the capacity for instrumental learning should return.
Although kappa agonists may impair learning when given immediately before testing,
model B predicts that the inhibitory actions of these compounds will prevent the
development of the behavioral deficit if they are given prior to uncontrollable shock.
These predictions made by model B suggest that the NMDA inhibitory nature of kappa
agonists undermine plasticity under some conditions but can be used to prevent
overexcitation in others.
The current experiment examines the impact of opioid agonists on instrumental
learning to test the predictions made by these contradictory models.  Experiment 1,
which consisted of three separate experiments, examined the impact of kappa
(Experiment 1A), mu (Experiment 1B), and delta (Experiment 1C) receptor agonists on
instrumental learning 10 minutes after drug treatment.  Experiments 2 and 3 examined
the dose-response relationship (Experiment 2) and timecourse (Experiment 3) of the
kappa-2 receptor agonist, GR89696.  Finally, Experiment 4 investigated the interaction
between GR89696 and uncontrollable shock.
8GENERAL METHOD
Subjects
Male Sprague-Dawley rats obtained from Harlan (Houston, TX) served as
subjects.  Animals were approximately 100-120 days old and weighed between 360 and
460 g.  Subjects were maintained on a 12-hr light-dark schedule and housed individually.
Food and water was available ad libitum, and behavioral testing was performed during
the light portion of the cycle.
Surgery
Subjects were anesthetized with pentobarbital (50 mg/kg, i.p.), and the area
surrounding the shoulders was shaved and sterilized with iodine.  An anterior-posterior
incision, approximately 1.5 cm long, was made over the 2nd thoracic vertebra (T2).  The
tissue immediately anterior to T2 was then cleared, and the exposed spinal cord was
transected using cauterization.  The resulting space was filled with Gelfoam (Harvard
Apparatus, Holliston, MA), and a cannula consisting of 25 cm of polyethylene tubing
(PE-10, VWR International, Bristol, CT) fitted with a stainless steel wire (0.09 mm
diameter) (Small Parts Inc., Miami Lakes, FL) was inserted into the subarachanoid space
on the dorsal surface of the cord.  The cannula was inserted 9 cm down the vertebral
column, and the exposed end of the tubing was secured externally to the skin with
cyanoacrylate, as described by Yaksh and Rudy (1976).  The wound caudal to the
exposed tubing was closed with Michel Clips (Fine Science Tools, Foster City, CA), and
the stainless steel wire was carefully removed.
9Rats were injected with 0.9% saline (2.5 ml, i.p.) immediately following surgery,
and the hindlimbs were secured in a natural flexed position with a piece of porous tape
(Ortholetic 1.3 cm width) wrapped once around the body and legs to prevent muscular
damage due to unnatural extension during recovery.  Subjects were allowed to recover in
a temperature-controlled room (26.7°C) with food and water available ad libitum.
Bladder expression took place twice a day and immediately before any behavioral
procedures were conducted. At the end of testing, animals were euthanized with
pentobarbital (100 mg/kg).
Transections were confirmed by a) visually inspecting the cord during surgery, b)
observing behavior after recovery to ensure complete paralysis below the forelimbs and
no vocalization when exposed to leg shock, and c) examining the cord post mortem in a
randomly selected subset of subjects.
Apparatus
Uncontrollable shock was administered while rats were loosely restrained in
opaque black Plexiglas tubes that were 22 cm in length and 6.8 cm in diameter.   A flat
floor constructed from a sheet of black Plexiglas 5.5 cm wide was attached 5.3 cm below
the top of the tube, and chamber fans provided approximately 60 dB of background
noise.  Tailshock was delivered using an electrode constructed from a modified fuse clip.
The electrode was coated with electrocardiogram (ECG) gel (Harvard Apparatus,
Holliston, MA) and secured with porous tape approximately 6 cm behind the base of the
tail. Constant-current 1.5-mA shock was delivered using a 660-V transformer.  A
Macintosh computer controlled the onset and offset of shock.
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Instrumental testing was conducted while rats were loosely restrained in tubes
(23.5 cm [length] x 8 cm [internal diameter]); see Grau et al., 1998, Figure 1).  Two slots
in the tube, (5.6 cm [length] x 1.8 cm [width]), 4 cm apart, 1.5 cm from the end of the
tube), allowed both hind legs to hang freely.  Shock was delivered using a BRS/LVE
(Laurel, MD) shock generator (Model SG-903).  Two electrodes, one inserted into the
skin (approximately 1.5 cm above the tarsals) and another inserted into the tibialis
anterior muscle (approximately 1.7 cm above the first electrode), were connected to a
computer-controlled relay that regulated the application of leg shock.
Leg position was monitored during testing using a contact electrode constructed
from a 7.0 cm long, 0.46 mm diameter stainless steel rod taped to the foot.  The last 2.5
cm of the electrode was insulated from the foot with heat-shrink tubing.  A fine wire
(0.01 sq mm [36 AWG], [l] x 20 cm) attached to the end of the rod extended from the
rear of the foot and was connected to a digital input monitored by a Macintosh computer.
A plastic rectangular dish (11.5 cm [w] x 19 cm [l] x 5 cm [d]) containing a NaCl
solution was placed approximately 7.5 cm below the restraining tube.  A drop of soap
was added to the solution to reduce surface tension.  A ground wire was then connected
to a 1.0 mm wide stainless steel rod, which was placed in the solution.  When the contact
electrode attached to the rat's paw touched the solution (indicating an extended ankle
joint), it completed the circuit monitored by the computer and delivered a shock to the
tibialis anterior.  The state of this circuit was sampled at a rate of 30 times/s.
Flexion force was measured prior to testing by attaching a monofilament plastic
line ("4 lb test" Stren, Dupont, Wilmington DE) to the rat's foot immediately behind the
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plantar protuberance.  The 40 cm length of line was passed through an eyelet attached to
the apparatus directly under the paw, 16 cm beneath the base of the tube.  The end of the
line was attached to a strain gauge (Fort-1000, World Precision Instruments, New
Haven, CT) fastened to a ring stand.  After the line was connected to the rat's paw, the
ring stand was positioned so that the line was taut, just barely registering on the gauge.
The strain gauge was calibrated by determining the relationship between voltage and
force in Newtons.
Instrumental Learning Testing Procedure
All subjects were allowed to recover for 24 hours following surgery, and the
hindlimbs were shaved and marked for electrode placement prior to testing.  A wire
electrode was then inserted through the skin over the distal portion of the tibialis anterior
(1.5 cm from the plantar surface of the foot), and one lead from the generator was
attached to this wire.  A contact electrode was secured to the foot between the second
and third digits with a piece of porous tape.  The shock generator was set to deliver a 0.4
mA shock, and the proximal portion of the tibialis anterior (approximately 1.7 cm
proximal to the wire electrode) was probed with a 2.5-cm stainless steel pin attached to a
shock lead to find a robust flexion response.  The pin was then inserted 0.4 cm into the
muscle.  A strain gauge was utilized to verify that a single, intense (1.6 mA, 0.3 s), test
shock elicited at least a 0.8 N flexion force.  Next, shock intensity was set at a level that
elicited a flexion force of 0.4 N.
To minimize lateral leg movements, a 20 cm piece of porous tape was wrapped
around the leg and was attached to a bar extending across the apparatus directly under
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the front panel of the restraining tube.  The tape was adjusted so that it was taut enough
to slightly extend the knee.  Finally, three short (0.15 s) shock pulses were applied, and
the level of the salt solution was adjusted so that the tip of the contact electrode (attached
to the rat’s foot) was submerged 4.0 mm below the surface of the water.  The rat’s
capacity to perform the instrumental response was then tested with exposure to 30 min
of controllable shock.  Whenever the rat’s leg fell below the level of the salt solution, the
electrodes delivered a shock to the tibialis anterior muscle, causing the ankle to flex.
Behavioral Measures
Three behavioral measures—response number, response duration and time in
solution—were used to assess a subject’s capacity to perform the instrumental response
(see Grau et al., 1998).  Performance was measured over time in 30 1-min time bins. The
computer monitoring leg position recorded an increase in response number whenever the
contact electrode left the salt solution.  Response duration was derived from time in
solution and response number using the following equation: Response Durationi = (60 s
– time in solutioni)/(Response Numberi + 1), where i is the current time bin.
Statistical Analysis
The effects of experimental treatment over time were analyzed using a repeated
measures analysis of variance (ANOVA).  Group differences were further evaluated
using Duncan’s New Multiple Range post hoc tests.
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EXPERIMENT 1
We have previously shown that only kappa antagonists given immediately before
testing eliminate the behavioral deficit induced by uncontrollable shock (Joynes & Grau,
2004).  If the deficit results from activation of kappa receptors, then an agonist for this
receptor should substitute for uncontrollable shock and produce the behavioral deficit.
Furthermore, we would not expect a delta or mu opioid receptor agonist to cause a
deficit.  The current experiment tests this hypothesis.
The kappa opioid receptor is thought to exist in at least two forms, kappa-1 and
kappa-2, both of which exist within the spinal cord (Caudle et al., 1994, 1998; Zukin,
Eghbali, Olive, Unterwald, & Tempel, 1988).  The prior study by Joynes and Grau
(2004) implicated the kappa receptor but did not differentiate between receptor subtypes.
The present study addressed this issue by using two different kappa opioid receptor
agonists, each selective for either the kappa-1 or kappa-2 subtype.
Experiment 1 consisted of three independent experiments. Experiment 1A
examined the issue of kappa opioid receptor specificity using a kappa-1 (U69593) or
kappa-2 (GR89696) opioid receptor agonist. Experiment 1B assessed the impact of a mu
opioid receptor agonist (DAMGO) on instrumental learning.  Finally, Experiment 1C
tested whether the delta opioid receptor agonist, DPDPE, induced a behavioral deficit.
All drugs were administered intrathecally (i.t.) at equal molar (30 nmol) concentrations.
This dose was chosen based on previous work by Ho et al. (1997) that examined the
impact of these opioid agonists on hyperalgesia.
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Method
In all experiments, leg electrodes were implanted, and rats were placed in the
instrumental testing apparatus (as described in the General Method section) with their
cannula threaded through an airhole in the tube for administration of drug, 24 hours
following surgery.  A baseline flexion force was taken before subjects received any
pharmacological agents, and shock intensity was adjusted to yield a flexion response of
0.4 N. After an initial flexion force was obtained, subjects received intrathecal
administration of 10 µl of drug (30nmol) or saline followed by a 10 µl saline flush using
a Hamilton syringe.  Flexion force was re-recorded 10 minutes after drug treatment to
ensure that the drug did not disrupt the flexion response, and shock intensity was re-
adjusted accordingly. Subjects were then tested with 30 minutes of controllable shock to
either the right or left hindlimb in a counterbalanced fashion.
Results
Experiment 1A:  Impact of kappa agonists.  To ensure that the drug treatment did
not affect baseline behavioral reactivity, the shock intensity required to produce a 0.4 N
change in flexion force both before and after drug administration were analyzed.  Mean
shock intensity needed to elicit a 0.4 N change in flexion force before drug treatment
ranged from 0.51 (+ 0.05) to 0.58 (+ 0.06) mA and after drug administration ranged
from 0.51 (+ 0.06) to 0.66 (+ 0.07) mA.  An ANOVA failed to yield any significant
effects of U69593 or GR89696 on shock intensity either before or after drug delivery, all
Fs < 1.42, p > .05.
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The effect of U69593 and GR89696 on our primary measure of learning,
response duration, is depicted in Figure 1A.  As in prior studies, saline-treated animals
exhibited increased response durations over time.  This learning was blocked by
GR89696, whereas U69593 had no effect.  A repeated measures ANOVA on response
duration revealed significant main effects of drug, F(2, 21) = 4.68, p < .05 and time,
F(29, 609) = 3.06, p < .01.  A significant Drug X Time interaction was also found, F(58,
609) = 1.76, p < .01. Post hoc comparisons of the group means, displayed in Figure 1B,
revealed that only subjects that received GR89696 prior to testing differed from the other
groups, p < .05.  No other group differences were significant, p > .05.
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Figure 1.  The impact of U69593 and GR89696 administered 10 minutes prior to instrumental testing
on response duration (A) and response number (C) over time.  The right panels (B & D) represent
group means (+SE) for response duration and response number, respectively.
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Figure 1C summarizes the impact of U69593 and GR89696 on response number.
All subjects, except those given GR89696 prior to testing, displayed a decrease in
response number as they acquired the instrumental response.  Rats given GR89696 failed
to learn and, consequently, exhibited a high level of responding during testing.
However, these group differences did not reach statistical significance, all Fs < 3.18, p >
.05.
Experiment 1B:  Impact of a mu agonist.  Mean shock intensity before drug
administration ranged from 0.53 (+ 0.06) to 0.56 (+ 0.06) mA and after drug treatment
ranged from 0.57 (+ 0.06) to 0.61 (+ 0.07) mA.  No significant group differences were
found for shock intensity either before or after treatment with DAMGO, all Fs < 1.0, p >
.05.
Figure 2A depicts the effect of DAMGO on response duration across time.
Saline-treated animals exhibited an increase in response durations over the 30-minute
testing period.  DAMGO had no impact on this learning. An ANOVA revealed a main
effect of time, F(29, 406) = 2.66, p <. 001. Neither the main effect of drug nor the Drug
X Time interaction approached significance, both Fs < 1.0, p > .05.
Figure 2C shows the effect of DAMGO on response number. As saline-treated
subjects learned the instrumental response they showed a progressive decrease in the
number of responses made over the thirty-minute testing period.  DAMGO-treated
subjects displayed a similar pattern of results.  An ANOVA on this measure revealed
only a significant main effect of time, F(29, 406) = 1.93, p < .01.  Neither the main
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effect of drug nor the Drug X Time interaction reached significance, both Fs < 1.0, p >
.05.
Experiment 1C:  Impact of a delta agonist. Mean shock intensity needed to
induce a 0.4 N change in flexion force before drug treatment ranged from 0.64 (+ 0.09)
to 0.67 (+ 0.07) and after treatment ranged from 0.67 (+ 0.06) to 0.69 (+ 0.09). One-way
ANOVAs on shock intensity both before and after administration of DPDPE revealed no
significant effects of the drug, all Fs < 1.0, p > .05.
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Figure 2.  Response duration (A) and number of responses (C) made by subjects that received
DAMGO 10 minutes prior to instrumental testing across time.  The right panels (B & D) display the
group means (+SE) for response duration and response number, respectively.
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The effect of DPDPE on response duration is depicted in Figure 3A.  Subjects
that received saline prior to testing exhibited an increase in response duration over the
testing period. DPDPE treatment had no effect on this learning.  An ANOVA yielded
only a significant main effect of time, F(29, 464) = 3.42, p <. 001.  Neither the main
effect of drug nor the Drug X Time interaction reached significance, both Fs < 1.0, p >
.05.
Figure 3. The effect of DPDPE on response duration (A) and response number (C) in subjects tested
10 minutes after drug treatment.  The group means (+SE) for response duration and response number
are presented in the right panels (B & D), respectively.
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The effect of DPDPE on response number is depicted in Figure 3C.  Saline-
treated subjects displayed a decrease in response number as they acquired the
instrumental response.
Although DPDPE-treated animals exhibited a higher level of responding across
the test period, there was not a significant effect of drug treatment on response number,
nor a Drug X Time interaction, both Fs < 1.56, p > .05.  Only the main effect of time
reached significance, F(29, 464) = 1.96, p < .01.
In summary, Experiment 1A determined that when subjects were tested 10
minutes following drug delivery, only the selective kappa-2 opioid receptor agonist,
GR89696, disrupted learning.  The selective kappa-1 opioid receptor agonist, U69593,
had no such impact on learning.  Experiments 1B and 1C verified that mu (DAMGO)
and delta (DPDPE) opioid receptor agonists did not produce a deficit when subjects were
tested 10 minutes after administration.  These findings suggest that only the kappa-2
opioid receptor subtype plays a role in the behavioral deficit observed after
uncontrollable shock.
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EXPERIMENT 2
Experiment 1 found that only the selective kappa-2 opioid receptor agonist,
GR89696, disrupted instrumental learning.  Experiment 2 establishes the effective dose
by assessing the impact of GR89696 across three molar concentrations.
 Method
Twenty-four hours following spinal transection, subjects received intrathecal
administration of 10 µl of GR89696 at one of four doses (0, 1.2, 6, or 30 nmol) followed
by a 10 µl saline flush.  The cannula was removed ten minutes later, and the animals
were immediately tested for instrumental learning (as described in the General Methods
section).
Results
Experiment 1 determined that GR89696 had no impact on the shock intensity
necessary to produce a 0.4 N change in flexion force. The mean shock intensity after
drug treatment ranged from 0.38 (+ 0.05) to 0.47 (+ 0.03) mA and were not significant,
F(3, 20) < 1.0, p > .05.
The effect of GR89696 on response duration is depicted in panel A of Figure 4.
Subjects that received saline exhibited an increase in response duration over the 30-
minute testing period.  GR89696 disrupted this learning in a dose-dependent fashion. A
repeated measures ANOVA revealed significant main effects of dose and time, Fs >
3.37, p < .05.  The Time X Dose interaction failed to reach significance, F(87, 580) =
1.08, p > .05.  Post hoc comparisons of the group means, depicted in Figure 4B,
determined that subjects that received saline or the lowest dose of GR89696 (1.2 nmol)
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differed from the group that received the highest dose (30 nmol) of the drug, p < .05.  No
other group differences were significant, p > .05.
Figure 4C illustrates the impact of GR89696 on response number.  As vehicle-
treated subjects learned the instrumental response, they showed a progressive decrease in
the number of responses made over the 30-minute testing period.  GR89696 dose-
dependently prevented the acquisition of the flexion response, resulting in a steady
increase in the number of responses made. An ANOVA revealed a significant main
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Figure 4.  The impact of three doses of GR89696 on response duration (A) and response number (C)
across time in subjects tested 10 minutes following drug delivery.  The right panels (B & D) portray
the group means (+SE) for response duration and response number, respectively.
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effect of dose, F(3, 580) = 4.20, p < .05.  The main effect of time did not reach
significance, nor did the Time X Dose interaction, Fs < 1.02, p > .05.  Post hoc
comparisons of the group means, displayed in Figure 4D, determined that subjects that
received the highest dose of GR89696 (30 nmol) differed from those that received either
saline or the lowest dose of the drug (1.2 nmol), p < .05. No other group differences
were significant, p > .05.
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EXPERIMENT 3
Experiments 1 and 2 demonstrated that the kappa-2 opioid receptor agonist,
GR89696, impairs learning when subjects are tested 10 minutes after drug treatment.
The deficit observed after uncontrollable shock lasts at least 24 hours and wanes within
96 hours (Crown et al., 2002). Experiment 3 tests whether the deficit induced by
GR89696 follows a similar time course.  Because the long-term consequences of drug
treatment likely vary as a function of dose, 2 doses were tested (6 and 30 nmols).  Both
of these doses disrupted learning/performance when subjects were tested 10 minutes
after drug delivery.  Experiment 3 tests whether these doses affect performance when
testing is delayed by 24 or 96 hours.
Method
Twenty-four hours following surgery, subjects were brought to the instrumental
testing room and received intrathecal delivery of GR89696 (10 µl) at one of three doses
(0, 6, or 30 nmol) followed by a 10 µl saline flush.  The cannula was removed ten
minutes later, and all animals were returned to the recovery room, where they remained
until instrumental testing either 24 or 96 hours later, yielding a 3 (0, 6, or 30 nmol) X 2
(24 or 96 hr) factorial design. Subjects received daily injections of saline (2.5 ml, i.p.) to
prevent dehydration.  On the day of testing, rats were brought to the instrumental testing
room and tested for learning with 30 minutes of controllable shock.
Results
Mean (+ SEM) shock intensity ranged from 0.43 (+ 0.04) to 0.55 (+ 0.04) mA.
No significant group differences were observed on this measure, all Fs < 1.35, p > .05.
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Figure 5A depicts the impact of GR89696 on response duration when subjects
are tested 24 and 96 hours after drug delivery. All saline-treated rats, independent of
time point, exhibited increased response durations over the 30-minute testing period.
The lowest dose of GR89696 (6 nmol) had no effect on this learning at either time point.
However, the highest dose (30 nmol) of the drug disrupted learning at both the 24- and
96-hour time points.  A repeated measures ANOVA revealed significant main effects of
dose and time, Fs > 3.69, p < .05.  The main effect of test time did not reach
significance, nor did the Dose X Delay or the Dose X Delay X Time interactions, all Fs
< 1.05, p > .05.  Post hoc comparisons of the group means (Figure 5B) revealed that all
subjects in the 6 nmol group tested at either the 24- or 96-hour timepoint differed from
those in the 30 nmol group that were tested 24 hours after drug treatment, p < .05.
Subjects that received vehicle 24 hours prior to testing also differed from this group, p <
.05.  No other group differences were significant, p > .05.
All subjects, except those given the highest dose of GR89696 prior to testing,
displayed a decrease in response number as they acquired the instrumental response
(Figure 5C).  Rats that received the highest dose of drug 24 or 96 hours prior to testing
failed to learn and, consequently, exhibited a high level of responding during testing.  In
the latter portion of the test session, these subjects exhibited some habituation, which led
to a decrease in response number. However, an ANOVA failed to reveal any significant
effects, all Fs < 2.04, p > .05.
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To summarize, animals that received the highest dose of GR89696 failed to learn
when tested either 24 or 96 hours after treatment.  However, the lowest dose of the drug
did not impair learning at either time point.  This finding suggests that the deficit
induced by the high dose of GR89696 does not follow the same timecourse as
uncontrollable shock.  The drug may have a longer lasting effect possibly because the
highest dose induces a degenerative process that permanently alters the capacity for
learning.
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Figure 5.  The effect of GR89696 on response duration (panels A&B) and response number (panels
D&E) across time in subjects tested 24 and 96 hours after drug treatment. The group means (+SE) for
response duration and response number appear in the right panels (C&F), respectively.
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EXPERIMENT 4
If uncontrollable shock and GR89696 produce a long-term deficit because they
engage similar biochemical systems, as suggested by model A, then these two treatments
should summate to produce a more robust effect.  Alternatively, GR89696 may prevent
the induction of the behavioral deficit if it inhibits NMDA receptors during
uncontrollable shock as suggested in model B. This experiment tests these predictions.
Method
Twenty-four hours following surgery, subjects received intrathecal
administration of either saline or GR89696 (6 nmol) followed by uncontrollable
tailshock or nothing, yielding a 2 (saline or GR89696) X 2 (shock or nothing) design.
Ten minutes later the cannula was removed, and the animals were placed into opaque
back Plexiglas tubes (as described above). Three pieces of porous tape were extended
across the tube to loosely restrain the subject, and an electrode coated with ECG gel was
secured approximately 6 cm behind the base of the tail with a piece of porous tape.  Rats
then received 6 minutes of uncontrollable tailshock (1.5 mA, intermittent) or an equal
amount of tube restraint (no shock).  After shock treatment, subjects were returned to the
recovery room until they were tested for instrumental learning 24 hours later.
Results
Mean (+ SEM) shock intensity ranged from 0.40 (+ 0.05) to 0.45 (+ 0.02) mA.
No significant group differences were observed on this measure, all Fs < 0.69, p > .05.
The effect of GR89696 administered prior to uncontrollable shock on response
duration is presented in Figure 6A. Unshocked saline controls displayed increased
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response durations over the 30-minute testing period.  Uncontrollable shock disrupted
this learning, an effect that was attenuated by GR89696.  A two-way, repeated measures
ANOVA revealed a significant main effect of time, F(29, 580) = 4.03, p < .05, and a
significant Drug X Shock X Time three-way interaction, F(29, 580) = 2.62, p < .05.  To
further characterize this interaction, one-way ANOVAs were used to evaluate the impact
of GR89696 in shocked and unshocked subjects, independently.  In shocked rats, drug
treatment significantly improved performance over time, F(29, 290) = 1.82, p < .05.
Drug treatment did not have a significant effect in the unshocked subjects, F(29, 290) =
4.45, p < .05.
Figure 6C illustrates the impact of GR89696 treatment given prior to
uncontrollable shock on response number.  Saline-treated subjects that received
uncontrollable shock prior to testing displayed a higher rate of responding than any other
group as they failed to acquire the instrumental response.  The impact of shock treatment
was attenuated by GR89696.  An ANOVA uncovered a significant Drug X Shock
interaction, F(1, 20) = 4.70, p < .05.  No other significant effects were found, p > .05.
In summary, there was no indication that the long-term effect of the kappa
agonist and shock showed additivity to produce a more robust long-term deficit.  Instead,
GR89696 attenuated the induction of the behavioral deficit when delivered prior to
uncontrollable shock.  This protective effect may be mediated through its action on the
NMDA receptor.
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Figure 6.  The impact of GR89696 administered prior to uncontrollable shock on response duration (A)
and response number (C) across time.  Subjects were tested 24 hours after shock exposure.  The right
panels (B & D) represent the group means (+SE) for response duration and response number,
respectively.  US=unshocked; Shk=shocked.
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DISCUSSION AND SUMMARY
The findings from Experiment 1 support the hypothesis that the behavioral deficit
induced by uncontrollable shock results from activation of the kappa opioid receptor
system, specifically the kappa-2 subtype.  This finding complements previous studies
demonstrating that nor-BNI, a kappa receptor antagonist, prevents the deficit if given
immediately before testing (Joynes & Grau, 2004).  Because nor-BNI has a higher
affinity for the kappa-1 receptor (Randic et al., 1995), the earlier data appeared to
implicate this form of the kappa receptor.  However, nor-BNI exhibits cross reactivity
with the kappa-2 receptor (Ni et al., 1995).  Further, the kappa-2 receptor is the
predominant form within the lumbosacral region of the spinal cord (Gouarderes,
Audigier, & Cros, 1982; Gouarderes, Attali, Audigier, & Cros, 1983, Caudle et al.,
1998), where instrumental learning appears to occur (Liu, Crown, Miranda, & Grau,
2002).  These observations, in conjunction with the relative effectiveness of the kappa-1
and kappa-2 agonists, suggest that instrumental learning is modulated by the kappa-2
receptor.
Both of the biochemical models of NMDA modulation by kappa agonists predict
that higher doses of GR89696 will disrupt learning.  Experiment 1 only examined the
impact of a relatively high dose of the drug; therefore, we examined the dose response
function in Experiment 2.  We found that GR89696 disrupts learning in a dose-
dependent fashion when administered 10 minutes prior to instrumental testing.  This
result supports biochemical model B, which predicts that both high and low doses will
impair learning through NMDA inhibition.  Model A predicts that low, non-toxic doses
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of the drug could facilitate learning by enhancing NMDA function. Within the dose
range tested, there was no evidence that GR89696 facilitated learning.
Joynes and Grau (2004) previously showed that a kappa opioid antagonist
inhibits the expression of the deficit, but not its induction.  The latter suggests that kappa
opioid release per se does not underlie the long-term consequences of shock treatment.
Experiment 3 addressed this issue by testing whether GR89696 impaired learning when
subjects were tested 24 and 96 hours after treatment.  We found that only the highest
dose (30 nmol) of GR89696 produced a long-lasting impairment that outlasted the
typical effect of uncontrollable shock.  This finding supports the prediction made by
model A that high doses of a kappa agonist could have long-term effects.  However, the
result that a lower dose (6 nmol), which had a short-term effect, did not produce a long-
term learning deficit supports models A and B, which both predict that low doses will
not produce any long-term consequences.  This outcome was not surprising given that
there is no evidence suggesting that low doses of GR89696 induce long-lasting changes
to the NMDA receptor system.  Therefore, it should not have any impact once it has
cleared the system.
The impairment produced by the highest dose of GR89696 may persist longer
than 96 hours because it produces a more robust, longer-lasting deficit than that seen
after uncontrollable shock.  Extending the time between drug treatment and testing
beyond 96 hours would answer this question.  If learning does not return after an
extended period of time, an alternative explanation, such as cell death, may be more
feasible. Supporting this, research has shown that intrathecal infusion of high doses of
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dynorphin into lower regions of the spinal cord causes motor impairment accompanied
by neuronal cell loss (Bakshi et al., 1992; Caudle & Isaac, 1987).  This cell loss was
evident 24 hours after injection (Gaumann, Grabow, Yaksh, Casey, & Rodriguez, 1990)
and appears to involve activation of caspase-3 and mitochondrial release of cytochrome
c (Singh et al., 2003).  Interestingly, we observed cell death in the lower lumbar regions
of the spinal cord of subjects exposed to uncontrollable stimulation that peaked 24 hours
after exposure (Liu et al., 2003).  This evidence supports the prediction made by model
A that high doses of a kappa agonist exacerbate NMDA-mediated overexcitation to
produce permanent cell loss and a long-term disruption of learning.
Experiment 4 found that GR89696 did not worsen the consequences of
uncontrollable shock as model A predicted.  Instead, GR89696 protected spinal cord
neurons from the consequences of uncontrollable stimulation.  This protective effect
may be mediated by the inhibition of NMDA receptor function, proposed in model B,
during uncontrollable stimulation.  This finding has important clinical implications for
both maladaptive (central sensitization) and adaptive (instrumental learning) plasticity in
the spinal cord.  Indeed, others have shown certain kappa agonists can be used to prevent
and reverse hyperalgesia and allodynia in animal models of neuropathic pain (Eliav et
al., 1999; Ho et al., 1997). Our work suggests that kappa agonists can be used to
preserve adaptive forms of plasticity within the spinal cord.
Overall, the results from this study suggest that kappa agonists have both
beneficial and detrimental effects on instrumental learning.  They produce a long-lasting
behavioral deficit at high doses and cause a short-term behavioral deficit when lower
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concentrations are present in the system during instrumental testing.  However, kappa
agonists can also protect spinal cord neurons against the consequences of uncontrollable
stimulation.  These contradictory findings can be rationalized in the following way:
Kappa agonists exert both antinociceptive and pronociceptive effects mediated through
kappa and NMDA receptors, respectively.  From an evolutionary perspective, this
system may have developed both antinociceptive and pronociceptive properties to allow
escape from danger (antinociceptive) and protection of the damaged tissue (hyperalgesia
and allodynia) once the threat has passed (Caudle & Mannes, 2000).  Lai and colleagues
(2001) suggest that these nociceptive effects are regulated by the amount of endogenous
kappa opioids released into the system after noxious input, with low concentrations
resulting in inhibition of neuronal activity (analgesia) and higher concentrations (from
sustained release) resulting in excitation of spinal cord neurons (pain and/or loss of
function).  Based on this idea, excessive amounts of endogenous kappa opioids would
accumulate following CNS injury and could lead to the development of central
sensitization (neuropathic pain) and loss of plasticity, both of which could hinder
recovery of function.  This outcome is predicted by model A and supported by our
finding that high doses of a kappa agonist produce a long-lasting behavioral deficit.
Treatment strategies that prevent this accumulation of endogenous kappa opioids after
injury, like kappa opioid antagonists, would indeed foster recovery of function.
In addition to the amount of kappa opioids in the cord, other factors, such as the
type of noxious input, may influence the effects of these peptides.  For example, we have
shown that continuous uncontrollable shock produces antinociception in the tail-flick
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test and does not impair learning (Crown et al., 2002).  An equivalent amount of
uncontrollable intermittent shock, on the other hand, does not induce antinociception in
the tail-flick test, but rather induces a tactile allodynia (Ferguson et al., 2000) and
impairs learning for up to 24 hours (Crown et al., 2002).  One interpretation of these
findings is that continuous shock elicits an endogenous kappa opioid release that protects
the cord, whereas intermittent shock engages a maladaptive release that disrupts spinal
cord plasticity.
The finding that kappa agonists inhibit instrumental learning within the spinal
cord mirrors results from earlier studies examining the role of opioids in learning and
memory.  The impact of opioids in areas of the brain associated with reward has been
extensively investigated (Beluzzi & Stein, 1977; Mucha & Herz, 1985); however, this
discussion will only focus on forms of learning and memory associated with the
hippocampus.  The simplicity of the hippocampus has made it an ideal structure for
studying the neurobiological mechanisms of learning and memory.  Three major
pathways exhibit LTP in the hippocampus: the perforant-path, the Schaffer collateral,
and the mossy fibers (Morris & Johnston, 1995).  NMDA receptor activation induces
LTP within the perforant-path and the Schaffer collaterals but not in the mossy fibers.
The coexistence of glutamate and opioids within the mossy fibers led researchers to
speculate that opioids modulate plasticity at these synapses (Morris & Johnston, 1995).
Further investigation revealed that, in general, mu and delta receptor activation enhances
synaptic plasticity in the hippocampus, whereas activation of kappa receptors inhibits it
(Terman, Wagner, & Chavkin, 1994; Wagner et al., 1993; Weisskopf, Zalutsky, &
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Nicoll, 1993).  Behavioral studies demonstrating that opioids affect spatial memory
extend these findings.  Doses of naloxone that block kappa receptors improve spatial
memory in the radial maze task (Gallagher, King, & Young, 1983; Collier &
Routtenberg, 1984), and microinjection of dynorphin into the hippocampus impairs
spatial learning in the Morris water maze (Sandin et al., 1998). The results from these
hippocampal studies support the idea put forth by model B that kappa agonists inhibit
NMDA receptor function and that any form of learning that depends on this receptor
system will be impaired by kappa receptor activation.  Collectively, these findings
indicate that opioids play a pivotal role in learning and memory processes in the
hippocampus.  Our work suggests that these effects may be conserved across the nervous
system, including the spinal cord.
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